Diasome Competitors and Similar CompaniesClear all
Diasome's competitors and similar companies include Lobesity, InVivo Therapeutics, MannKind Corporation and Hua Medicine.
 Diasome Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. |  Lobesity Lobesity (also known as Lobesity Investors) is a company engaged in the clinical and commercial development of therapies to treat obesity and related disorders. |  InVivo Therapeutics InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. |  MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients. | ||
Founding Date | Founding Date 2004 | Founding Date 2015 | Founding Date 2005 | Founding Date 1991 | Founding Date 2011 |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cleveland, US HQ | Locations Cleveland, US HQ | Locations Cambridge, US HQ | Locations Westlake Village, US HQ Danbury, US | Locations Shanghai, CN HQ Beijing, CN Wuhan, CN Hong Kong, HK |
Employees | Employees 1515% increase | Employees 1 | Employees 6 | Employees 39513% increase | Employees 168 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 995.9 k | Valuation ($) 1.9 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $349m (FY, 2025) | Revenue (est.) ¥492.9m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $26.8m (FY, 2025) | Cost of goods ¥180.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $322.2m (FY, 2025) | Gross profit ¥1.6b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income ($10.5m) (FY, 2022) | Net income $5.9m (FY, 2025) | Net income ¥1.1b (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 30m (almost 9 years ago) | Latest funding round $ 722.5k (almost 11 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 42.9m | Total funding raised $ 722.5k | Total funding raised $ 75.2m | Total funding raised $ 200m | Total funding raised $ 242.4m |
For sources of this data, please see the company profile
View Company Profiles
Lobesity
HQ
Cleveland, US
Employees
1
Lobesity (also known as Lobesity Investors) is a company engaged in the clinical and commercial development of therapies to treat obesity and related disorders.
View companyInVivo Therapeutics
HQ
Cambridge, US
Employees
6
InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries.
View companyMannKind Corporation
HQ
Westlake Village, US
Employees
395↑ 13% increase
MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.
View company
Hua Medicine
HQ
Shanghai, CN
Employees
168
Hua Medicine (华领医药) is a drug development company.
View company